Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Histologic scoring systems specific for primary sclerosing cholangitis (PSC) are not validated. We recently determined the applicability and prognostic value of three histological scoring systems in a single PSC cohort. The aim of this study was to validate their prognostic use and reproducibility across a multicenter PSC cohort. Liver biopsies from PSC patients were collected from seven European institutions. Histologic scoring was performed using the Nakanuma, Ishak, and Ludwig scoring systems. Biopsies were independently scored by six liver pathologists for interobserver agreement. The prognostic value of clinical, biochemical, and all three histologic scoring systems on predicting composite endpoints 1 (PSC‐related death and liver transplantation), 2 (liver transplantation), and 3 (liver‐related events), was assessed using univariable and multivariable Cox proportional hazards modeling. A total of 119 PSC patients were identified, and the median follow‐up was 142 months. During follow‐up, 31 patients died (20 PSC‐related deaths), 31 patients underwent liver transplantation, and 35 patients experienced one or more liver‐related events. All three staging systems were independent predictors of endpoints 2 and 3 (Nakanuma system: hazard ratio [HR], 3.16 [95% confidence interval (CI), 1.49‐6.68] for endpoint 2 and HR, 2.05 [95% CI, 1.17‐3.57] for endpoint 3; Ishak system: HR, 1.55 [95% CI, 1.10‐2.18] for endpoint 2 and HR, 1.43 [95% CI, 1.10‐1.85] for endpoint 3; Ludwig system: HR, 2.62 [95% CI, 1.19‐5.80] for endpoint 2 and HR, 2.06 [95% CI, 1.09‐3.89] for endpoint 3). Only the Nakanuma staging system was independently associated with endpoint 1: HR, 2.14 (95% CI, 1.22‐3.77). Interobserver agreement was moderate for Nakanuma stage (κ = 0.56) and substantial for Nakanuma component fibrosis (κ = 0.67), Ishak stage (κ = 0.64), and Ludwig stage (κ = 0.62). Conclusion: We confirm the independent prognostic value and demonstrate for the first time the reproducibility of staging disease progression in PSC using the Nakanuma, Ishak, and Ludwig staging systems. The Nakanuma staging system—incorporating features of chronic biliary disease—again showed the strongest predictive value. (H epatology 2017;65:907‐919).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Boonstra, K., Weersma, R. K., van Erpecum, K. J., Rauws, E. A., Spanier, B. W. M., Poen, A. C., van Nieuwkerk, K. M., Drenth, J. P., Witteman, B. J., Tuynman, H. A., et al. (2013) · Hepatology · doi:10.1002/hep.26565 · Cited by 725 · cited 2×
“The proportion of PSC/AIH-overlap patients (13%) included in the present study was relatively high when compared with the 4-7% reported in large epidemiologic studies(11, 19).”
BackgroundResultSelf-citationHammel, P., Couvelard, A., O'Toole, D., Ratouis, A., Sauvanet, A., Fléjou, J. F., Degott, C., Belghiti, J., Bernades, P., Valla, D., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102083440604 · Cited by 427
Tischendorf, J. J. W., Hecker, H., Krüger, M., Manns, M. P., & Meier, P. N. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00872.x · Cited by 413
Corpechot, C., Gaouar, F., El Naggar, A., Kemgang, A., Wendum, D., Poupon, R., Carrat, F., & Chazouillères, O. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.12.030 · Cited by 300
Self-citationClinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome
Floreani, A., Rizzotto, E. R., Ferrara, F., Carderi, I., Caroli, D., Blasone, L., & Baldo, V. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41841.x · Cited by 230
Nakanuma, Y., Zen, Y., Harada, K., Sasaki, M., Nonomura, A., Uehara, T., Sano, K., Kondo, F., Fukusato, T., Tsuneyama, K., et al. (2010) · Pathology International · doi:10.1111/j.1440-1827.2009.02500.x · Cited by 224 · cited 4×
“The Nakanuma grading system includes degree of cholangitis activity (score 0-3), and hepatitis activity (score 0-3)(9), while the Ishak grading system evaluates degree of interface hepatitis (score 0-4), confluent necrosis”
BackgroundMethodInfluentialEnhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis
Vesterhus, M., Hov, J. R., Holm, A., Schrumpf, E., Nygård, S., Godang, K., Andersen, I. M., Næss, S., Thorburn, D., Saffioti, F., et al. (2015) · Hepatology · doi:10.1002/hep.27825 · Cited by 138
Self-citationPathologic Features and Evolution of Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis
Scheuer, P. J. (1998) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)63652-5 · Cited by 106
Kakuda, Y., Harada, K., Sawada-Kitamura, S., Ikeda, H., Sato, Y., Sasaki, M., Okafuji, H., Mizukoshi, E., Terasaki, S., Ohta, H., et al. (2013) · Human Pathology · doi:10.1016/j.humpath.2012.09.017 · Cited by 81
Review article: the reversibility of cirrhosis
Sohrabpour, A. A., Mohamadnejad, M., & Malekzadeh, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12044 · Cited by 80
Trivedi, P. J., Corpechot, C., Pares, A., & Hirschfield, G. M. (2016) · Hepatology · doi:10.1002/hep.28128 · Cited by 71 · cited 3×
“Through risk stratification (into low/high risk for poor outcome) patient subgroups that potentially have the greatest benefit from inclusion and treatment in clinical trials may be identified using their initial liver biopsy(4).”
BackgroundSelf-citationPortmann, B., & Zen, Y. (2012) · Histopathology · doi:10.1111/j.1365-2559.2011.03853.x · Cited by 70
P1198 : Histological stage is relevant for risk-stratification in primary biliary cirrhosis
Carbone, M., Sharp, S. J., Heneghan, M. A., Neuberger, J. M., Hirschfield, G. M., Burroughs, A. K., Thorburn, D., Bathgate, A., Aldersley, M., Adgey, C., et al. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)31394-5 · Cited by 15
Self-citation
Cited by
Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
“clinical outcomes [221] and is still considered a robust surrogate endpoint for clinical trials in PSC [222].”
BackgroundPrimary sclerosing cholangitis – a comprehensive review
Karlsen, T. H., Folseraas, T., Thorburn, D., & Vesterhus, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.022 · Cited by 868
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma
Bowlus, C. L., Arrivé, L., Bergquist, A., Deneau, M., Forman, L., Ilyas, S. I., Lunsford, K. E., Martinez, M., Sapisochin, G., Shroff, R., et al. (2023) · Hepatology · doi:10.1002/hep.32771 · Cited by 428
Fibrosis and alcohol-related liver disease
Lackner, C., & Tiniakos, D. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.12.003 · Cited by 322
Hirschfield, G. M., Chazouillères, O., Drenth, J. P., Thorburn, D., Harrison, S. A., Landis, C. S., Mayo, M. J., Muir, A. J., Trotter, J. F., Leeming, D. J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.035 · Cited by 187
Self-citation
Metadata
- Authors
- de Vries, E. M. G., de Krijger, M., Färkkilä, M., Arola, J., Schirmacher, P., Gotthardt, D., Goeppert, B., Trivedi, P. J., Hirschfield, G. M., Ytting, H., Vainer, B., Buuren, H. R. V., Biermann, K., Harms, M. H., Chazouilleres, O., Wendum, D., Kemgang, A. D., Chapman, R. W., Wang, L. M., Williamson, K. D., Gouw, A. S. H., Paradis, V., Sempoux, C., Beuers, U., Hübscher, S. G., Verheij, J., & Ponsioen, C. Y.
- Venue
- Hepatology
- Published
- 2017-01-11
- Volume
- 65
- Issue
- 3
- Pages
- 907-919
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2552444756
- Cited by
- 104
- References
- 15
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.